{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:55:28Z","timestamp":1781344528985,"version":"3.54.1"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2681354","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T08:59:50Z","timestamp":1781341190000},"page":"1649-1662","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Potential implications of increased utilization of oral nirmatrelvir\/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective"],"prefix":"10.1080","volume":"29","author":[{"given":"Jennifer","family":"Benner","sequence":"first","affiliation":[{"name":"Stratevi, LLC","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Lee","sequence":"additional","affiliation":[{"name":"Stratevi, LLC","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cianciolo","sequence":"additional","affiliation":[{"name":"Stratevi, LLC","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tendai","family":"Mugwagwa","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"de Lossada","sequence":"additional","affiliation":[{"name":"Pfizer SLU","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Peral","sequence":"additional","affiliation":[{"name":"Pfizer SLU","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sussman","sequence":"additional","affiliation":[{"name":"Stratevi, LLC","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"e_1_3_7_2_1","unstructured":"World Health Organization. COVID-19 epidemiological update \u2013 15 July 2024. 2024."},{"key":"e_1_3_7_3_1","unstructured":"Centro de Coordinaci\u00f3n de Alertas y Emergencias Sanitarias. Actualizaci\u00f3n n\u00b0 672. Enfermedad por el coronavirus (COVID-19). 2023."},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08454-y"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1488283"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-23077-5"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043335"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2024.08.012"},{"key":"e_1_3_7_9_1","unstructured":"European Medicines Agency. Paxlovid (nirmatrelvir\/ritonavir) 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid."},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00118-4"},{"key":"e_1_3_7_12_1","volume-title":"Why are billions of euros worth of COVID drug Paxlovid going to waste in Europe","author":"Min R.","year":"2024","unstructured":"Min R. Why are billions of euros worth of COVID drug Paxlovid going to waste in Europe?. Lyon, France: EuroNews; 2024. https:\/\/www.euronews.com\/health\/2024\/02\/24\/why-are-billions-of-euros-worth-of-covid-drug-paxlovid-going-to-waste-in-europe"},{"key":"e_1_3_7_13_1","unstructured":"Pfizer Signs Agreement to Provide the European Union with PAXLOVID. 2022. https:\/\/www.pfizer.com\/news\/announcements\/pfizer-signs-agreement-provide-european-union-paxlovidtm"},{"key":"e_1_3_7_14_1","unstructured":"Pfizer. Data-on-file. 2025."},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2025.106912"},{"key":"e_1_3_7_16_1","doi-asserted-by":"crossref","unstructured":"Marcano-Belisario J Hartley L Phan NTN et al. Economic systematic literature of paxlovid for the treatment of patients with mild to moderate COVID-19. ISPOR; May 13-16. Montreal Quebec Canada; 2025.","DOI":"10.1016\/j.jval.2025.04.1770"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12040026"},{"key":"e_1_3_7_18_1","unstructured":"Yeung K Whittington MD Beinfeld M et al. Special assessment of outpatient treatments for COVID-19; final evidence report and meeting summary. Institute for Clinical and Economic Review; 2022."},{"key":"e_1_3_7_19_1","unstructured":"European Medicines Agency. Lagevrio (molnupiravir). 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lagevrio#:\u223c:text=Application%20withdrawn Medicine%20Human"},{"key":"e_1_3_7_20_1","unstructured":"European Medicines Agency. Veklury. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury"},{"key":"e_1_3_7_21_1","unstructured":"European Medicines Agency. Xevudy. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xevudy"},{"key":"e_1_3_7_22_1","unstructured":"European Medicines Agency. Withdrawn applications and products. 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-public-health-emergency-international-concern-2020-23\/withdrawn-applications-products#covid-19-treatments-withdrawn-from-rolling-review-14508"},{"key":"e_1_3_7_23_1","unstructured":"National Results for Series 2024-2074: Population residing in Spain on January 1 by sex age and year [Internet]. 2025. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=36643#_tabs-tabla."},{"key":"e_1_3_7_24_1","unstructured":"Instituto de Salud Carlos III-Centro Nacional de Epidemiolog\u00eda. Vigilancia de Infecci\u00f3n Respiratoria Aguda: gripe COVID-19 y VRS Semana 34\/2025 (del 18 de agosto al 24 de agosto de 2025). 2025."},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30264-3"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071049"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae551"},{"key":"e_1_3_7_28_1","unstructured":"Instituto de Salud Carlos III. Flu COVID-19 and other respiratory viruses. 2025. https:\/\/cne.isciii.es\/en\/servicios\/enfermedades-transmisibles\/enfermedades-a-z\/gripe-covid-19-y-otros-virus-respiratorios"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55599"},{"key":"e_1_3_7_30_1","unstructured":"Instituto de Salud Carlos III-Centro Nacional de Epidemiolog\u00eda. 6\u00b0 informe Efectividad de la campa\u00f1a de vacunaci\u00f3n frente a COVID-19 en Espa\u00f1a en oto\u00f1o de 2022. 2023."},{"key":"e_1_3_7_31_1","unstructured":"Ministerio de S. GIV COVID-19: gesti\u00f3n integral de la vacunaci\u00f3n COVID-19. 2024."},{"key":"e_1_3_7_32_1","unstructured":"Instituto de Salud Carlos III-Centro Nacional de Epidemiolog\u00eda. Informe n\u00b0 182. Situaci\u00f3n de COVID-19 en Espa\u00f1a. 2023."},{"key":"e_1_3_7_33_1","unstructured":"El Registro de Actividad Sanitaria Especializada (RAE-CMBD) [Internet]. 2025. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S\/rae-cmbd"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00327-0"},{"key":"e_1_3_7_35_1","unstructured":"Resultados nacionales (desde el trimestre 1\/2008): Componentes del coste laboral total [Internet]. 2025. https:\/\/www.ine.es\/dyngs\/INEbase\/operacion.htm?c=Estadistica_C&cid=1254736045053&idp=1254735976596"},{"issue":"3","key":"e_1_3_7_36_1","doi-asserted-by":"crossref","first-page":"e70288","DOI":"10.1002\/jmv.70288","article-title":"Cost-effectiveness of nirmatrelvir\/ritonavir in COVID-19 patients at high-risk for progression in Spain","volume":"97","author":"Azanza JR","year":"2025","unstructured":"Azanza JR, Gonz\u00e1lez Del Castillo JM, Ferrando R, et al. Cost-effectiveness of nirmatrelvir\/ritonavir in COVID-19 patients at high-risk for progression in Spain. J Med Virol. 2025;97(3):e70288.","journal-title":"J Med Virol"},{"key":"e_1_3_7_37_1","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. FICHA TECNICA PAXLOVID 150\u2009MG + 100\u2009MG COMPRIMIDOS RECUBIERTOS CON PELICULAAvailable from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1221625001\/FT_1221625001.html#1."},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01168-0"},{"key":"e_1_3_7_39_1","unstructured":"Ocupados por sexo y grupo de edad. Valores absolutos y porcentajes respecto del total de cada sexo [Internet]. 2025. https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=4076"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.907"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.09.025"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf187"},{"key":"e_1_3_7_43_1","doi-asserted-by":"crossref","unstructured":"Sandin R Harrison C Draica F et al. Estimated impact of oral nirmatrelvir;ritonavir on reductions in hospitalizations and associated costs within high-risk COVID-19 patients in the US. research square. 2022.","DOI":"10.21203\/rs.3.rs-2191067\/v1"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.12.1290"},{"key":"e_1_3_7_45_1","doi-asserted-by":"crossref","unstructured":"Greasley SE Noell S Plotnikova O et al. Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2. bioRxiv2022.01.17.476556. 2022.","DOI":"10.1101\/2022.01.17.476556"},{"key":"e_1_3_7_46_1","doi-asserted-by":"crossref","unstructured":"Rai DK Yurgelonis I McMonagle P et al. Nirmatrelvir an orally active Mpro inhibitor is a potent inhibitor of SARS-CoV-2 Variants of Concern. bioRxiv2022.01.17.476644. 2022.","DOI":"10.1101\/2022.01.17.476644"},{"key":"e_1_3_7_47_1","doi-asserted-by":"crossref","unstructured":"Rosales R McGovern BL Rodriguez ML et al. Nirmatrelvir Molnupiravir and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant. bioRxiv. 2022.01.17.476685. 2022.","DOI":"10.1101\/2022.01.17.476685"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.10.026"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2579407"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13679"},{"key":"e_1_3_7_51_1","unstructured":"Registro Nacional de Fracturas de Cadera. RNFC INFORME 2023 ANUAL. 2023."},{"key":"e_1_3_7_52_1","unstructured":"Ministerio de Sanidad. GIV COVID-19: Gesti\u00f3n integral de la vacunaci\u00f3n COVID-19. 2023."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2681354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:00:08Z","timestamp":1781341208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2681354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2681354"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2681354","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}